Biomarkers of Bone Resorption in Metastatic Prostate Cancer

University of Aberdeen

Status: Completed

Conditions: Metastatic Prostate Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01233557

10/S0802/36

Details and patient eligibility

About

Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness. Changes in these biomarkers will be correlated with the patient's treatment with antiandrogen therapy and bisphosphonates and the response and/or progression of their cancer. It is hoped that serial measurement of these biomarkers may allow therapeutic monitoring in the future with successful individualisation of bisphosphonate therapy for metastatic prostate cancer.

Enrollment: 40 patients

Sex: Male

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• prostate cancer with bone metastases
• hormone sensitive

Exclusion criteria

• inadequate renal function
• ongoing dental problems
• previous bisphosphonate therapy

Trial design

40 participants in 1 patient group

Bone Metastases